Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Food Effect of THB001 in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Food Effect of THB001 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs THB 001 (Primary)
  • Indications Chronic urticaria
  • Focus Adverse reactions; First in man
  • Acronyms TBA
  • Sponsors Third Harmonic Bio

    • Most Recent Events

    • 27 Feb 2023 Results assessing safety,pharmacokinetics (PK) and pharmacodynamics (PD) of THB001 in healthy participants presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 09 Nov 2022 According to a Third Harmonic Bio. media release, company expects to present full results of the trial at an upcoming medical meeting during the first half of 2023.
    • 09 Aug 2022 Status changed from not yet recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top